Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan. The transaction involved 11.569 ADS at a price of $58.6439 per ADS, executed on 2026-03-02 on the New York Stock Exchange.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan. The transaction involved 11.569 ADS at a price of $58.6439 per ADS, executed on 2026-03-02 on the New York Stock Exchange.
GSK plc reports that it bought back 630,000 ordinary shares on 3 March 2026 at a volume‑weighted average price of 2,139.22p, with prices ranging from 2,116.00p to 2,169.00p per share. The shares will be held in treasury as part of its existing share buyback programme executed through BNP Paribas under a non‑discretionary agreement announced on 17 February 2026.
Since that date, GSK has repurchased a total of 5,266,000 ordinary shares. After this latest transaction, it holds 245,157,094 ordinary shares in treasury and has 4,071,005,394 ordinary shares in issue, all carrying voting rights. The percentage of voting rights represented by the treasury shares is confirmed at 6.02%, a figure shareholders can use when assessing disclosure thresholds for holdings.
GSK plc reports that it bought back 630,000 ordinary shares on 3 March 2026 at a volume‑weighted average price of 2,139.22p, with prices ranging from 2,116.00p to 2,169.00p per share. The shares will be held in treasury as part of its existing share buyback programme executed through BNP Paribas under a non‑discretionary agreement announced on 17 February 2026.
Since that date, GSK has repurchased a total of 5,266,000 ordinary shares. After this latest transaction, it holds 245,157,094 ordinary shares in treasury and has 4,071,005,394 ordinary shares in issue, all carrying voting rights. The percentage of voting rights represented by the treasury shares is confirmed at 6.02%, a figure shareholders can use when assessing disclosure thresholds for holdings.
GSK plc has completed its previously announced acquisition of RAPT Therapeutics, valuing RAPT at an approximate aggregate equity value of $2.2 billion, with GSK’s upfront cash investment around $1.9 billion net of cash acquired.
The deal gives GSK global rights to the food-allergy candidate ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong. Ozureprubart is a long-acting anti-IgE monoclonal antibody in phase IIb development, aiming for 12‑week dosing versus current 2–4 week injections and potentially serving patients currently ineligible for existing anti‑IgE therapy.
Phase IIb monotherapy data from the prestIgE trial are expected in 2027, with phase III studies planned in at‑risk adult and paediatric populations. GSK will also assume success‑based milestone and royalty obligations for ozureprubart owed to Shanghai Jeyou Pharmaceutical.
GSK plc has completed its previously announced acquisition of RAPT Therapeutics, valuing RAPT at an approximate aggregate equity value of $2.2 billion, with GSK’s upfront cash investment around $1.9 billion net of cash acquired.
The deal gives GSK global rights to the food-allergy candidate ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong. Ozureprubart is a long-acting anti-IgE monoclonal antibody in phase IIb development, aiming for 12‑week dosing versus current 2–4 week injections and potentially serving patients currently ineligible for existing anti‑IgE therapy.
Phase IIb monotherapy data from the prestIgE trial are expected in 2027, with phase III studies planned in at‑risk adult and paediatric populations. GSK will also assume success‑based milestone and royalty obligations for ozureprubart owed to Shanghai Jeyou Pharmaceutical.
GSK plc reports that on 2 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas, at a volume‑weighted average price of 2,180.14p, with prices ranging between 2,168.00p and 2,195.00p per share.
The shares will be held as treasury stock under GSK’s existing buyback programme. Since 17 February 2026, GSK has bought 4,636,000 ordinary shares. After this purchase, it holds 244,527,094 shares in treasury and has 4,071,635,394 voting shares in issue, with treasury shares representing 6.01% of voting rights.
GSK plc reports that on 2 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas, at a volume‑weighted average price of 2,180.14p, with prices ranging between 2,168.00p and 2,195.00p per share.
The shares will be held as treasury stock under GSK’s existing buyback programme. Since 17 February 2026, GSK has bought 4,636,000 ordinary shares. After this purchase, it holds 244,527,094 shares in treasury and has 4,071,635,394 voting shares in issue, with treasury shares representing 6.01% of voting rights.
RAPT Therapeutics was acquired via a completed tender offer by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc for $58.00 per share. The offer expired at one minute after 11:59 P.M. Eastern on March 2, 2026, and 30,137,567 Shares were validly tendered, representing 93.36% of issued and outstanding Shares as of that time.
Because the Minimum Condition was satisfied, Purchaser accepted the tendered Shares and will pay for them promptly. Under Section 251(h) of the DGCL, Ultimate Parent, Parent and Purchaser intend to effect the Merger without a stockholder meeting, delist the Shares from Nasdaq, and take steps to terminate registration and suspend reporting as promptly as practicable.
RAPT Therapeutics was acquired via a completed tender offer by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc for $58.00 per share. The offer expired at one minute after 11:59 P.M. Eastern on March 2, 2026, and 30,137,567 Shares were validly tendered, representing 93.36% of issued and outstanding Shares as of that time.
Because the Minimum Condition was satisfied, Purchaser accepted the tendered Shares and will pay for them promptly. Under Section 251(h) of the DGCL, Ultimate Parent, Parent and Purchaser intend to effect the Merger without a stockholder meeting, delist the Shares from Nasdaq, and take steps to terminate registration and suspend reporting as promptly as practicable.
GSK plc reports that, acting through BNP Paribas, it repurchased 430,000 ordinary shares on 27 February 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,153.00p and 2,197.00p per share, at a volume‑weighted average price of 2,179.36p.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back a total of 4,136,000 ordinary shares. Following this latest transaction, GSK holds 244,027,094 shares in treasury and has 4,072,135,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 5.99% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 430,000 ordinary shares on 27 February 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,153.00p and 2,197.00p per share, at a volume‑weighted average price of 2,179.36p.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back a total of 4,136,000 ordinary shares. Following this latest transaction, GSK holds 244,027,094 shares in treasury and has 4,072,135,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 5.99% of voting rights.
GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.
After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.
GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.
After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.
GSK plc reports that, on 26 February 2026, it bought 545,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at a volume‑weighted average price of 2,186.88p per share.
The shares will be held as treasury shares. After this transaction, GSK holds 243,597,094 shares in treasury and has 4,072,555,332 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 5.98% of voting rights.
GSK plc reports that, on 26 February 2026, it bought 545,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at a volume‑weighted average price of 2,186.88p per share.
The shares will be held as treasury shares. After this transaction, GSK holds 243,597,094 shares in treasury and has 4,072,555,332 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 5.98% of voting rights.
GSK reports that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease.
The submission is based on the positive phase III GLISTEN trial, where linerixibat showed rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo, with a safety profile consistent with earlier studies and its IBAT-inhibitor mechanism. In China, primary biliary cholangitis affects about 280,000 people, and cholestatic pruritus can impact up to 89% of patients over the course of their disease, with few effective treatment options. Linerixibat has Orphan Drug Designation in the US, EU and Japan, and marketing applications are under review in the US, EU, UK and Canada, but it is not yet approved anywhere.
GSK reports that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease.
The submission is based on the positive phase III GLISTEN trial, where linerixibat showed rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo, with a safety profile consistent with earlier studies and its IBAT-inhibitor mechanism. In China, primary biliary cholangitis affects about 280,000 people, and cholestatic pruritus can impact up to 89% of patients over the course of their disease, with few effective treatment options. Linerixibat has Orphan Drug Designation in the US, EU and Japan, and marketing applications are under review in the US, EU, UK and Canada, but it is not yet approved anywhere.